Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy

Shim, Man Kyu; Moon, Yujeong; Yang, Suah; Kim, Jin-Seong; Cho, Hanhee; Lim, Seung Woon; Yoon, Hong Yeol; Seong, Joon Kyung; Kim, Kwangmeyung

doi:10.1016/j.biomaterials.2020.120347

Cited by 70 publications

(43 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, exosome-mediated transfer of apoptosis inducers such as circRNA and miRNA may help overcome chemotherapy resistance (91,136). Cancerspecific, pro-apoptotic drug-drug conjugate for SMAC and doxorubicin suppressed tumor growth in drug-resistant lung cancer model (137). Development of such nanoparticle designs might provide tumor-specific therapeutic options without drug resistance.…”

Section: Discussionmentioning

confidence: 99%

Targeting Apoptosis to Overcome Chemotherapy Resistance

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Targeting Apoptosis to Overcome Chemotherapy Resistance

et al. 2022

View full text Add to dashboard Cite

“…Platinum-containing dual drug chemotherapy is the cornerstone of advanced LUAD treatment [ 30 ]. Unfortunately, drug resistance reduces chemotherapy chemosensitivity dramatically, medication for patients with LUAD become tricky [ 31 ]. Therefore, screening high-sensitivity anti-tumor drugs is crucial for LUAD treatment.…”

Section: Discussionmentioning

confidence: 99%

Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD

Chen

Shen²,

et al. 2021

Aging

View full text Add to dashboard Cite

The tumor immune microenvironment of lung cancer is associated with prognosis and immunotherapy efficacy. Long noncoding RNAs are identified as prognostic biomarkers associated with immune functions. We constructed a signature comprising differentially expressed immune-related lncRNAs to predict the prognosis of patients with lung adenocarcinoma. We established the immune-related lncRNA signature by pairing immune-related lncRNAs regardless of expression level and lung adenocarcinoma patients were divided into high- and low-risk groups. The prognosis of patients in the two groups was significantly different; The immune-related lncRNA signature could serve as an independent lung adenocarcinoma prognostic indicator. The signature correlated negatively with B cell, CD4+ T cell, M2 macrophage, neutrophil, and monocyte immune infiltration. Patients with low risk scores had a higher abundance of immune cells and stromal cells around the tumor. Gene set enrichment analysis showed that samples from low-risk group were more active in the IgA production in intestinal immune network and the T and B cell receptor signaling pathway. High-risk groups had significant involvement of the cell cycle, DNA replication, adherens junction, actin cytoskeleton regulation, pathways in cancer, and TGF-β signaling pathways. High risk scores correlated significantly negatively with high CTLA-4 and HAVCR2 expression and higher median inhibitory concentration of common anti-tumor chemotherapeutics (e.g., cisplatin, paclitaxel, gemcitabine) and targeted therapy (e.g., erlotinib and gefitinib). We identified a reliable immune-related lncRNA lung adenocarcinoma prognosis model, and the immune-related lncRNA signature showed promising clinical prediction value.

show abstract

“…For instance, a novel pro-apoptotic drug-drug conjugate was obtained by Shim and co-workers through the conjugation of the pro-apoptotic peptide drug (SMAC; Ala-Val-Pro-Ile-Ala-Gln, AVPIAQ) and cathepsin B-cleavable peptide (Phe-Arg-Arg-Gly, FRRG) to DOX, resulting in SMAC-FRRG-DOX that self-assembled into NPs. Upon cellular uptake, the NPs were cleaved to obtain proapoptotic SMAC and cytotoxic DOX specifically in cancer cells that overexpress cathepsin B, inducing a synergic effect of the combined molecules in a metastatic LC model [133].…”

Section: Inhibition Of the Cell Deathmentioning

confidence: 99%

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Haider

Elsherbeny

Pittalà

et al. 2022

IJMS

View full text Add to dashboard Cite

Lung cancer (LC) is one of the leading causes of cancer occurrence and mortality worldwide. Treatment of patients with advanced and metastatic LC presents a significant challenge, as malignant cells use different mechanisms to resist chemotherapy. Drug resistance (DR) is a complex process that occurs due to a variety of genetic and acquired factors. Identifying the mechanisms underlying DR in LC patients and possible therapeutic alternatives for more efficient therapy is a central goal of LC research. Advances in nanotechnology resulted in the development of targeted and multifunctional nanoscale drug constructs. The possible modulation of the components of nanomedicine, their surface functionalization, and the encapsulation of various active therapeutics provide promising tools to bypass crucial biological barriers. These attributes enhance the delivery of multiple therapeutic agents directly to the tumor microenvironment (TME), resulting in reversal of LC resistance to anticancer treatment. This review provides a broad framework for understanding the different molecular mechanisms of DR in lung cancer, presents novel nanomedicine therapeutics aimed at improving the efficacy of treatment of various forms of resistant LC; outlines current challenges in using nanotechnology for reversing DR; and discusses the future directions for the clinical application of nanomedicine in the management of LC resistance.

show abstract

Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy

Cited by 70 publications

References 44 publications

Targeting Apoptosis to Overcome Chemotherapy Resistance

Targeting Apoptosis to Overcome Chemotherapy Resistance

Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD

Nanomedicine Strategies for Management of Drug Resistance in Lung Cancer

Contact Info

Product

Resources

About